News

A recent survey found COVID-19 death rates among both Black and white individuals were higher in areas with more residential segregation, with Black individuals’ death rates being almost twice as high.

Del Doherty, co-founder of Prodigy Rx, discusses how the PBM aims to give payers control so they can lower costs and can improve clinical and return-to-work outcomes.

Amneal is of 35 global companies selected to manufacture and commercialize generic version of COVID-19 treatment Paxlovid.

William Dietz, MD, PhD, Professor and Director of Sumner M. Redstone Global Center for Prevention and Wellness at George Washington University, addressed to MHE the degree obesity is a risk factor at for severe COVID-19 and what those reasons are for obesity increasing the risk. This video is in correlation to Managed Healthcare Executive's March Issue cover story highlighting the dangerous pairing of COVID-19 and Obesity.

New data show longer-term benefits from Aduhelm, which was approved last year to treat Alzheimer’s disease.

ICER analyzed two therapies — Cosela and plinabulin — to prevent chemotherapy-induced neutropenia and other myelosuppressive effects. Both moderately increased quality-adjusted life-years.

ICER also reviewed, plinabulin, which is development chemotherapy-induced neutropenia (CIN) and would achieve common thresholds for cost-effectiveness if priced between $1,100 and $1,600 per dose.

Aaron Glatt, MD, Chairman of the Department of Medicine and Chief of Infectious Diseases/Hospital Epidemiologist at Mount Sinai South Nassau and Clinical Professor of Medicine at the Icahn School of Medicine at Mount Sinai, addressed to MHE the degree obesity is a risk factor at for severe COVID-19 and what those reasons are for obesity increasing the risk. This video is in correlation to Managed Healthcare Executive's March Issue cover story highlighting the dangerous pairing of COVID-19 and Obesity.

The toll that Alzheimer’s disease takes on the health of those affected by the disease is enormous. And so is the associated expense.

In this week's episode, Briana Contreras, editor of Managed Healthcare Executive, spoke with Peter Durlach, chief strategy officer of Nuance. The two discussed how artificial intelligence drives value for patients and providers and how AI tools and solutions are helping health systems reach the quadruple aim of care.

Their application to the FDA included data showing that confirmed infections and severe illness were lower among individuals who received a second booster of the Pfizer-BioNTech vaccine.

Allan Coukell, Civica’s senior vice president of public policy, discusses how the generic manufacturer is disrupting the market for insulins.

A Johns Hopkins study found an association between use of e-cigarettes and prediabetes. More research is needed to tease out the possible causal elements of the association. Meanwhile, a federal government survey found that 1.72 million high school students and 320,000 middle schoolers are current users of e-cigarettes.

Evio Pharmacy Solutions plans to provide biosimilar alternatives for autoimmune and cancer therapeutics.

The American Cancer Society’s 2022 statistical report shows that the 30-year trend is continuing.

Saunders, co-founder at Intellihealth and assistant professor of Clinical Medicine at Weill Cornell Medical College, addressed to MHE the degree obesity is a risk factor at for severe COVID-19 and what those reasons are for obesity increasing the risk. This video is in correlation to Managed Healthcare Executive's March Issue cover story highlighting the dangerous pairing of COVID-19 and Obesity.

In an interim analysis, Keytruda/Lynparza did not improve overall survival in patients with metastatic castration-resistant prostate cancer who progressed after treatment with chemotherapy.

Research presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting found minority patients with asthma perceived lower quality interactions with their care team, but did not find significant differences in the prescription of biologic medications across racial/ethnic groups.

Voluntary guidelines passed in January show a way to making interoperability work on a practical level.

Home healthcare is booming, and precision medicine is going to create a demand for employees with new kinds of expertise. But people working in the healthcare are also likely to see growth in internal promotions, specifically for cross-collaboration and cross-functional roles.

A recently published review delves into the role that type 2 inflammation plays chronic rhinosinusitis and the evidence that agents that interfere with that inflammatory pathway could be used as treatments.

A large prospective study of the use of Rituxan (rituximab) and a biosimilar, Novex, has yielded safety data validating the use of this agent in pediatric patients with a wide range of diseases and conditions, ranging from oncologic and hematologic to neurologic.

The agency plans to convene an advisory committee to review the application of Nuplazid to treat Alzheimer’s psychosis. The FDA also approved an indication for Opdivo, okays a third biosimilar to blockbuster cancer treatment Neupogen, and issues complete response letter for long-acting HIV therapy.

Study adds to the evidence that reducing the risk of blood clots should be one of the main goals of managing these myeloproliferative disorders. Monitoring cholesterol levels may be especially important.

Besremi (ropeginterferon alfa-2b-njft) is the first interferon approved specifically as a treatment for polycythemia vera.

Anthem, which owns Blue Cross Blue Shield plans in 14 states, will need shareholder approval to make the change. The vote is scheduled to occur May 18.

JAK inhibitors, such as Jakafi (ruxolitinib), have helped improve outcomes and survival of patients with the rare blood cancer.